ERBB2 and breast neoplasm: To validate the proposed model and the findings in Fig. 5, model parameters were fit to measurements for the growth of HER2-Postive breast tumours in mice, with and without Herceptin treatment, (Lewis Phillips et al. 2008) (see Sect. 2.5 for more details).